NewAmsterdam Pharma Company N.V. (NAMS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 99.7%, operating margin -10.0%, net margin -9.1%.
At the current price of $21.18, NAMS has negative trailing earnings (P/E not meaningful) and an ROE of -29.82%. Market capitalisation stands at $2.5B.
Balance sheet quality for NAMS: current ratio of 7.9, net cash position of $636.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $21.18 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | NL |
Valuation Ratios
| Price / Book | 5.45 |
| EV / EBITDA | -14.54 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -29.82% |
| Return on Invested Capital | -33.01% |
| Return on Assets | -26.49% |
| Gross Margin | 99.74% |
| Operating Margin | -1002.90% |
| Net Margin | -905.74% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.88 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Company N.V. | $2.5B | 5.45 | -29.8% | |
| KYMR | Kymera Therapeutics, Inc. | $9.6B | 7.56 | ||
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | -55.4% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.6B | 6.34 | ||
| CGON | CG Oncology Inc. | $6.5B | 6.32 | -25.2% | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.5B | 27.12 | 5.63 |
Price Performance
| 1 month | -22.28% |
| 3 months | -29.00% |
| Year-to-date | -39.62% |
| 1 year | -13.52% |
| 3 years | +115.68% |
| 5 years | +115.90% |
52-Week Range
| 52-week High | $42.21 |
| 52-week Low | $21.02 |
| Avg Volume (90d) | 1.3M |
Related companies: ACLX · AKRO · CGON · CRNX · IMVT · KYMR · LGND
Explore sector: Healthcare · Biotechnology
More sections of NAMS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks